ARDENT HEALTH INC (ARDT) Stock Analyst Ratings
USA - NYSE:ARDT - US03980N1072 - Common Stock
15.02 USD
+0.21 (+1.42%)
ChartMill assigns a Buy % Consensus number of 81% to ARDT. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 19.84. This target is 32.12% above the current price.
ARDT was analyzed by 18 analysts. The buy percentage consensus is at 81. So analysts seem to be very confident about ARDT.
In the previous month the buy percentage consensus was at a similar level.
ARDT was analyzed by 18 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-14 | Goldman Sachs | Initiate | Neutral |
| 2025-09-10 | UBS | Initiate | Buy |
| 2025-08-11 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-08-07 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-07-16 | B of A Securities | Downgrade | Neutral -> Underperform |
| 2025-05-20 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-05-15 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-05-09 | Guggenheim | Maintains | Buy -> Buy |
| 2025-04-09 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-04-09 | Guggenheim | Initiate | Buy |
| 2025-04-01 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-03-26 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-03-04 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-02-27 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-01-21 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-01-06 | Truist Securities | Maintains | Buy -> Buy |
| 2024-11-14 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-11-12 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2024-11-06 | B of A Securities | Downgrade | Buy -> Neutral |
| 2024-10-11 | Keybanc | Initiate | Overweight |
| 2024-09-19 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2024-08-16 | Loop Capital | Maintains | Buy -> Buy |
| 2024-08-16 | Truist Securities | Reiterate | Buy -> Buy |
| 2024-08-15 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2024-08-12 | Leerink Partners | Initiate | Outperform |
| 2024-08-12 | Mizuho | Initiate | Outperform |
| 2024-08-12 | RBC Capital | Initiate | Outperform |
| 2024-08-12 | Loop Capital | Initiate | Buy |
| 2024-08-12 | Truist Securities | Initiate | Buy |
| 2024-08-12 | JP Morgan | Initiate | Neutral |
ARDENT HEALTH INC / ARDT FAQ
What do analysts expect the price target to be for ARDENT HEALTH INC (ARDT)?
18 analysts have analysed ARDT and the average price target is 19.84 USD. This implies a price increase of 32.12% is expected in the next year compared to the current price of 15.02.
What is the consensus rating for ARDT stock?
The consensus rating for ARDENT HEALTH INC (ARDT) is 81.1111 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for ARDT stock?
The number of analysts covering ARDENT HEALTH INC (ARDT) is 18.